Key facts
- This page summarizes Zaneta Odrowaz's Form 3 filing for Attovia Therapeutics, Inc. (ATTO).
- 0 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 04 Aug 2026, 19:33.
Zaneta Odrowaz - 04 Aug 2026 Form 3 Insider Report for Attovia Therapeutics, Inc. (ATTO)
- Reporting relationship
- Chief Business Officer
- Issuer ticker
- ATTO
- Reported as of
- 04 Aug 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ Steven Chan, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Zaneta Odrowaz filed Form 3 for Attovia Therapeutics, Inc. (ATTO) on 04 Aug 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002141590
Primary reporting owner
Odrowaz Zaneta
- Relationship
- Chief Business Officer
- Address
- C/O ATTOVIA THERAPEUTICS, INC., 1091 INDUSTRIAL ROAD, SUITE 310, SAN CARLOS
- Signature
- /s/ Steven Chan, Attorney-in-Fact
- Signature date
- 04 Aug 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ATTO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 103,269
- Date
- 04 Aug 2026
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ATTO
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 04 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,137
- Exercise price
- $1.58
- Footnotes
- F2
ATTO
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 04 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,382
- Exercise price
- $2.88
- Footnotes
- F3
ATTO
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 04 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 102,260
- Exercise price
- $3.53
- Footnotes
- F4
ATTO
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 04 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 85,037
- Exercise price
- $4.92
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
As of the date of this Form 3, 17,156 shares are unvested. The remaining shares will continue to vest monthly and will be fully vested on April 27, 2027, subject to continued service to the Issuer through each vesting period.
Footnote F2
The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares underlying the option vested on August 17, 2024, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the reporting person's continued service to the Issuer on each vesting date.
Footnote F3
The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares underlying the option vested on March 6, 2025, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the reporting person's continued service to the Issuer on each vesting date.
Footnote F4
The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares underlying the option vested on May 9, 2025, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the reporting person's continued service to the Issuer on each vesting date.
Footnote F5
The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares underlying the option vested on May 18, 2026, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the reporting person's continued service to the Issuer on each vesting date.